The road ahead for cervical cancer prevention and control

Current Oncology

Volumn 21, Issue 2, 2014, Pages

  Tota, Joseph E ^a   Ramana Kumar, A V ^a   El Khatib, Z ^a   Franco, E L ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

Cervical cancer; Human papillomavirus; Screening; Vaccination

Indexed keywords

PROTEIN E6; PROTEIN E7; WART VIRUS VACCINE;

COLPOSCOPY; COST EFFECTIVENESS ANALYSIS; DNA METHYLATION; GENOTYPE; HUMAN; ONSET AGE; PAPANICOLAOU TEST; PRECANCER; REVIEW; SAFETY; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX CANCER; VACCINATION; WART VIRUS;

EID: 84898830408     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.21.1720     Document Type: Review

References (78)

1. Papanicolaou GN, Traut HF. The diagnostic value of vaginal smears in carcinoma of the uterus. Am J Obstet Gynecol 1941;42:193-206.
2. Quinn M, Babb P, Jones J, Allen E. Effect of screening on incidence of and mortality from cancer of cervix in England: evaluation based on routinely collected statistics. BMJ 1999;318:904-8.
3. Arbyn M, Raifu AO, Weiderpass E, Bray F, Anttila A. Trends of cervical cancer mortality in the member states of the European Union. Eur J Cancer 2009;45:2640-8.
4. Jemal A, Ward E, Thun M. Declining death rates reflect progress against cancer. PLoS One 2010;5:e9584.
5. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-19.
6. Franco EL, Duarte-Franco E, Ferenczy A. Cervical cancer: epidemiology, prevention and the role of human papillomavirus infection. CMAJ 2001;164:1017-25.
7. Tota JE, Chevarie-Davis M, Richardson LA, Devries M, Franco EL. Epidemiology and burden of hpv infection and related diseases: implications for prevention strategies. Prev Med 2011;53(suppl 1):S12-21.
8. Arbyn M, Castellsague X, de Sanjose S, et al. Worldwide burden of cervical cancer in 2008. Ann Oncol 2011;22:2675-86.
9. Insinga RP, Dasbach EJ, Elbasha EH. Assessing the annual economic burden of preventing and treating anogenital human papillomavirus-related disease in the U.S.: analytic framework and review of the literature. Pharmacoeconomics 2005;23:1107-22.
10. Nanda K, McCrory DC, Myers ER, et al. Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. Ann Intern Med 2000;132:810-19.
11. Cuzick J, Clavel C, Petry KU, et al. Overview of the European and North American studies on hpv testing in primary cervical cancer screening. Int J Cancer 2006;119:1095-101.
12. Saslow D, Solomon D, Lawson HW, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin 2012;62:147-72.
13. Pollock S, Dunfield L, Shane A, et al. on behalf of the Canadian Task Force on Preventive Health Care. Recommendations on screening for cervical cancer. CMAJ 2013;185:35-45.
14. Arbyn M, Kyrgiou M, Simoens C, et al. Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: meta-analysis. BMJ 2008;337:a1284.
15. Sawaya GF, Kerlikowske K, Lee NC, Gildengorin G, Washington AE. Frequency of cervical smear abnormalities within 3 years of normal cytology. Obstet Gynecol 2000;96:219-23.
16. Franco EL, Duarte-Franco E, Ferenczy A. Prospects for controlling cervical cancer at the turn of the century. Salud Publica Mex 2003;45(suppl 3):S367-75.
17. Franco EL, Mahmud SM, Tota J, Ferenczy A, Coutlee F. The expected impact of hpv vaccination on the accuracy of cervical cancer screening: the need for a paradigm change. Arch Med Res 2009;40:478-85.
18. Tota J, Mahmud SM, Ferenczy A, Coutlee F, Franco EL. Promising strategies for cervical cancer screening in the post-human papillomavirus vaccination era. Sex Health 2010;7:376-82.
19. Ratnam S, Franco EL, Ferenczy A. Human papillomavirus testing for primary screening of cervical cancer precursors. Cancer Epidemiol Biomarkers Prev 2000;9:945-51.
20. Mayrand MH, Duarte-Franco E, Coutlee F, et al. Randomized controlled trial of human papillomavirus testing versus Pap cytology in the primary screening for cervical cancer precursors: design, methods and preliminary accrual results of the Canadian cervical cancer screening trial (cccast). Int J Cancer 2006;119:615-23.
21. Jemal A, Simard EP, Dorell C, et al. Annual Report to the Nation on the Status of Cancer, 1975-2009, featuring the burden and trends in human papillomavirus (hpv)-associated cancers and hpv vaccination coverage levels. J Natl Cancer Inst 2013;105:175-201.
22. Markowitz LE, Hariri S, Lin C, et al. Reduction in human papillomavirus (hpv) prevalence among young women following hpv vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003-2010. J Infect Dis 2013;208:385-93.
23. Franco EL, Tota J. Invited commentary: human papillomavirus infection and risk of cervical precancer-using the right methods to answer the right questions. Am J Epidemiol 2010;171:164-8.
24. Mayrand MH, Duarte-Franco E, Rodrigues I, et al. Human papillomavirus dna versus Papanicolaou screening tests for cervical cancer. N Engl J Med 2007;357:1579-88.
25. Cuzick J, Arbyn M, Sankaranarayanan R, et al. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine 2008;26(suppl 10):K29-41.
26. Richardson LA, Tota J, Franco EL. Optimizing technology for cervical cancer screening in high-resource settings. Expert Rev Obstet Gynecol 2011;6:343-53.
27. Ogilvie GS, van Niekerk DJ, Krajden M, et al. A randomized controlled trial of human papillomavirus (hpv) testing for cervical cancer screening: trial design and preliminary results (hpv focal trial). BMC Cancer 2010;10:111.
28. Leinonen M, Nieminen P, Kotaniemi-Talonen L, et al. Agespecific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting. J Natl Cancer Inst 2009;101:1612-23.
29. Khan MJ, Castle PE, Lorincz AT, et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (hpv) type 16 or 18 and the possible utility of type-specific hpv testing in clinical practice. J Natl Cancer Inst 2005;97:1072-9.
30. Kjaer S, Hogdall E, Frederiksen K, et al. The absolute risk of cervical abnormalities in high-risk human papillomavirus- positive, cytologically normal women over a 10-year period. Cancer Res 2006;66:10630-6.
31. Schweizer J, Lu PS, Mahoney CW, et al. Feasibility study of a human papillomavirus E6 oncoprotein test for diagnosis of cervical precancer and cancer. J Clin Microbiol 2010;48:4646-8.
32. Wentzensen N, Sherman ME, Schiffman M, Wang SS. Utility of methylation markers in cervical cancer early detection: appraisal of the state-of-the-science. Gynecol Oncol 2009;112:293-9.
33. Wentzensen N, Sun C, Ghosh A, et al. Methylation of HPV18, HPV31, and HPV45 genomes and cervical intraepithelial neoplasia grade 3. J Natl Cancer Inst 2012;104:1738-49.
34. Carozzi F, Confortini M, Dalla Palma P, et al. Use of p16- INK4A overexpression to increase the specificity of human papillomavirus testing: a nested substudy of the ntcc randomised controlled trial. Lancet Oncol 2008;9:937-45.
35. Cox JT, Castle PE, Behrens CM, Sharma A, Wright TC Jr, Cuzick J on behalf of the athena hpv Study Group. Comparison of cervical cancer screening strategies incorporating different combinations of cytology, hpv testing, and genotyping for hpv 16/18: results from the athena hpv study. Am J Obstet Gynecol 2012; 208:184.e1-11.
36. Cuzick J, Bergeron C, von Knebel Doeberitz M, et al. New technologies and procedures for cervical cancer screening. Vaccine 2012;30(suppl 5):F107-16.
37. Castle PE, Lorincz AT, Mielzynska-Lohnas I, et al. Results of human papillomavirus dna testing with the Hybrid Capture 2 assay are reproducible. J Clin Microbiol 2002;40:1088-90.
38. Carozzi FM, Del Mistro A, Confortini M, et al. Reproducibility of hpv dna testing by Hybrid Capture 2 in a screening setting. Am J Clin Pathol 2005;124:716-21.
39. Katki HA, Kinney WK, Fetterman B, et al. Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. Lancet Oncol 2011;12:663-72.
40. Murphy J, Kennedy EB, Dunn S, et al. on behalf of the Ontario Cervical Screening Program and the Program in Evidence- Based Care. Cervical screening: a guideline for clinical practice in Ontario. J Obstet Gynaecol Can 2012;34:453-8.
41. Sasieni P, Castanon A, Cuzick J. Effectiveness of cervical screening with age: population based case-control study of prospectively recorded data. BMJ 2009;339:b2968.
42. Castle PE, Sideri M, Jeronimo J, Solomon D, Schiffman M. Risk assessment to guide the prevention of cervical cancer. J Low Genit Tract Dis 2008;12:1-7.
43. Wright TC Jr, Stoler MH, Behrens CM, Apple R, Derion T, Wright TL. The athena human papillomavirus study: design, methods, and baseline results. Am J Obstet Gynecol 2012;206:46.e1-11.
44. Schiffman M, Clifford G, Buonaguro FM. Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderline. Infect Agent Cancer 2009;4:8.
45. Munoz N, Bosch FX, Castellsague X, et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 2004;111:278-85.
46. de Sanjose S, Quint WG, Alemany L, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010;11:1048-56.
47. Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006;367:1247-55.
48. Garland SM, Hernandez-vila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007;356:1928-43.
49. Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER on behalf of the Centers for Disease Control and Prevention (cdc) and the Advisory Committee on Immunization Practices (acip). Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (acip). MMWR Recomm Rep 2007;56:1-24.
50. Centers for Disease Control and Prevention (cdc). fda licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated hpv vaccination recommendations from the Advisory Committee on Immunization Practices (acip). MMWR Morb Mortal Wkly Rep 2010;59:626-9.
51. Brotherton JM, Fridman M, May CL, Chappell G, Saville AM, Gertig DM. Early effect of the hpv vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. Lancet 2011;377:2085-92.
52. Niccolai LM, Julian PJ, Meek JI, McBride V, Hadler JL, Sosa LE. Declining rates of high-grade cervical lesions in young women in Connecticut, 2008-2011. Cancer Epidemiol Biomarkers Prev 2013;22:1446-50.
53. Centers for Disease Control and Prevention (cdc). National and state vaccination coverage among adolescents aged 13-17 years-United States, 2011. MMWR Morb Mortal Wkly Rep 2012;61:671-7. [Erratum in: MMWR Morb Mortal Wkly Rep 2012;61:844]
54. Centers for Disease Control and Prevention (cdc). Adult vaccination coverage-United States, 2010. MMWR Morb Mortal Wkly Rep 2012;61:66-72.
55. Porta M. The improbable plunge. What facts refute reasons to expect that the effectiveness of hpv vaccination programs to prevent cervical cancer could be low? Prev Med 2009;48:407-10.
56. Slade BA, Leidel L, Vellozzi C, et al. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. JAMA 2009;302:750-7.
57. Dillner J, Kjaer SK, Wheeler CM, et al. on behalf of the future i/ii Study Group. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ 2010;341:c3493.
58. Lehtinen M, Paavonen J, Wheeler CM, et al. on behalf of the hpv patricia Study Group. Overall efficacy of hpv-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind patricia trial. Lancet Oncol 2012;13:89-99.
59. Roteli-Martins CM, Naud P, De Borba P, et al. Sustained immunogenicity and efficacy of the hpv-16/18 AS04-adjuvanted vaccine: up to 8.4 years of follow-up. Hum Vaccin Immunother 2012;8:390-7.
60. Tota JE, Ramanakumar AV, Jiang M, et al. Epidemiological approach to evaluate the potential for human papillomavirus type replacement post-vaccination. Am J Epidemiol 2013;178:625-34.
61. Brown DR, Kjaer SK, Sigurdsson K, et al. The impact of quadrivalent human papillomavirus (hpv; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine hpv types in generally hpv-naive women aged 16-26 years. J Infect Dis 2009;199:926-35.
62. Wheeler CM, Castellsague X, Garland SM, et al. on behalf of the hpv patricia Study Group. Cross-protective efficacy of hpv-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic hpv types: 4-year end-of-study analysis of the randomised, double-blind patricia trial. Lancet Oncol 2012;13:100-10.
63. Van de Velde N, Boily MC, Drolet M, et al. Population-level impact of the bivalent, quadrivalent, and nonavalent human papillomavirus vaccines: a model-based analysis. J Natl Cancer Inst 2012;104:1712-23.
64. Kreimer AR, Rodriguez AC, Hildesheim A, et al. on behalf of the cvt Vaccine Group. Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent hpv16/18 vaccine. J Natl Cancer Inst 2011;103:1444-51.
65. Neuzil KM, Canh do G, Thiem VD, et al. Immunogenicity and reactogenicity of alternative schedules of hpv vaccine in Vietnam: a cluster randomized noninferiority trial. JAMA 2011;305:1424-31.
66. Giuliano AR, Palefsky JM, Goldstone S, et al. Efficacy of quadrivalent hpv vaccine against hpv infection and disease in males. N Engl J Med 2011;364:401-11.
67. Centers for Disease Control and Prevention (cdc). Recommendations on the use of quadrivalent human papillomavirus vaccine in males-Advisory Committee on Immunization Practices (acip), 2011. MMWR Morb Mortal Wkly Rep 2011;60:1705-8.
68. Brisson M, van de Velde N, Franco EL, Drolet M, Boily MC. Incremental impact of adding boys to current human papillomavirus vaccination programs: role of herd immunity. J Infect Dis 2011;204:372-6.
69. Chesson HW, Ekwueme DU, Saraiya M, Dunne EF, Markowitz LE. The cost-effectiveness of male hpv vaccination in the United States. Vaccine 2011;29:8443-50.
70. Wilson SE, Harris T, Sethi P, Fediurek J, Macdonald L, Deeks SL. Coverage from Ontario, Canada's school-based hpv vaccine program: the first three years. Vaccine 2013;31:757-62.
71. Poland GA, Jacobson RM. The clinician's guide to the antivaccinationists' galaxy. Hum Immunol 2012;73:859-66.
72. Hedlund J. Risky business: safety regulations, risks compensation, and individual behavior. Inj Prev 2000;6:82-90.
73. Forster AS, Marlow LA, Stephenson J, Wardle J, Waller J. Human papillomavirus vaccination and sexual behaviour: cross-sectional and longitudinal surveys conducted in England. Vaccine 2012;30:4939-44.
74. Liddon NC, Leichliter JS, Markowitz LE. Human papillomavirus vaccine and sexual behavior among adolescent and young women. Am J Prev Med 2012;42:44-52.
75. Franco EL, de Sanjose S, Broker TR, et al. Human papillomavirus and cancer prevention: gaps in knowledge and prospects for research, policy, and advocacy. Vaccine 2012;30(suppl 5):F175-82.
76. Peres J. For cancers caused by hpv, two vaccines were just the beginning. J Natl Cancer Inst 2011;103:360-2.
77. Bagarazzi ML, Yan J, Morrow MP, et al. Immunotherapy against hpv16/18 generates potent TH1 and cytotoxic cellular immune responses. Sci Transl Med 2012;4:155ra38.
78. Barrios K, Celis E. TriVax-hpv: an improved peptide-based therapeutic vaccination strategy against human papillomavirus- induced cancers. Cancer Immunol Immunother 2012;61:1307-17.